[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504138":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":62,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":26,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"59th Medical Wing","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nanodroper","EXPERIMENTAL","* Patients are given a Nanodropper to use with their IOP-lowering eyedrops.\n* Patient returns for a safety check 1 month following the start of Nanodropper use.\n* At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops without Nanodropper for 3 months.\n* The patient returns at 6 months for final clinical assessment",[13],"Device: Nanodropper",{"label":15,"type":16,"description":17,"interventionNames":18},"Regular Dropper","ACTIVE_COMPARATOR","* Patient continues using current IOP-lowering eyedrops without Nanodropper adaptor.\n* At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops with Nanodropper for 3 months.\n* Patient returns for a safety check 1 month following the start of Nanodropper use.\n* The patient returns at 6 months for final clinical assessment",[19],"Device: Regular dropper",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Nanodropper","Nanodropper delivers 1\u002F5 of eye drop volume compared to regular droppers",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Regular dropper","Delivers full eye drop volume",[15],[32],{"name":33,"affiliation":5,"role":34},"Alexandra Papp, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jose E Capo-Aponte, OD, PhD","CONTACT","210-292-2554","Jose.E.CapoAponte.ctr@health.mil",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Jennifer Steger, PhD","507-405-5676","jenny@nanodropper.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Wilford Hall Ambulatory Surgical Center","RECRUITING","Lackland Air Force Base","Texas","78236","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-98.61797,29.38663,{"lat":58,"lon":57},[61],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[65],{"name":66,"class":67},"Nanodropper, Inc.","INDUSTRY","100504138","nanodropper-use-in-primary-open-angle-glaucoma-patients-a-non-inferiority-trial-100504138",false,"NCT05844384","Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial","Inclusion Criteria:\n\n* POAG\u002FOHTN patients above the age of 18 years.\n* On a maximum of 2 IOP lowering medications.\n* Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.\n\nExclusion Criteria:\n\n* Glaucoma not of the POAG or OHTN variety or other retinal diseases.\n* Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).\n* Using more than 2 IOP-lowering medications.\n* IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.","ALL","18 Years",{"count":77,"type":78},30,"ESTIMATED","INTERVENTIONAL",[81],"NA","This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.",[84,85],"Ocular Hypertension","Primary Open Angle Glaucoma",[23,85,87,84],"Microdrops","2023-05-03",{"date":90,"type":91},"2023-05-06","ACTUAL",{"date":93,"type":91},"2022-03-17",{"date":95,"type":78},"2024-03-17",{"name":5,"class":6},1]